Highest-materiality recent filing
CFO Bradford Amman resigns; Roman Franklin appointed CFO via CFO Portal effective July 31, 2026
Amman receives 250,000 fully vested shares, option for 150,000 shares, and $13,333/month advisory fee for 180 days.
Vivos Therapeutics raises ~$2.1M in PIPE of convertible preferred and warrants
Sold 3,608,496 units at $0.582/unit; each unit: one Series A Convertible Preferred (stated value $0.456) and one warrant (exercise $0.456, 5-year term).
Vivos Therapeutics announces proposed rights offering with exercise price floor of $1.25 per share
Each right entitles holder to buy one share at greater of $1.25/share or 20% above market on day before record date.
Vivos enters collaboration with Florida cardiology group to launch AIM Florida sleep apnea venture
Vivos expects to hold ≥80% membership interest in AIM Florida; SPCVA up to 20%, subject to definitive docs.
Vivos Therapeutics enters debt-to-equity exchange; receives Nasdaq bid price deficiency notice
Exchange agreement to convert up to $4.5M of Streeterville debt into non-convertible preferred and common stock, contingent on equity financings of at least $2.6M (first tranche) by June 15, 2026.
Vivos Therapeutics gets Nasdaq delisting notice for negative equity of $1.55M
Negative stockholders' equity of ~$1.55M as of Dec 31, 2025, below Nasdaq's $2.5M minimum requirement.
Vivos Therapeutics FY2025 revenue up 16% to $17.5M; operating loss widens to $19.9M
FY2025 revenue $17.5M, +16% YoY from $15.0M; driven by sleep testing services and SCN acquisition.
Sold 1,353,625 shares, pre-funded warrant for 429,957 shares, and Series A/B warrants for 1,783,582 each at $1.34 per unit.
Vivos Therapeutics raises $4.6M via warrant exercise and issues new warrants for 3.96M shares
Gross proceeds of ~$4.6M from immediate cash exercise of existing warrants at reduced price of $2.34/share.
Vivos Therapeutics enters $5.5M convertible note with V-Co, initial $900k funded
Note up to $5.5M principal (incl. 10% OID) from V-Co Investors 3 LLC, affiliate of existing investor New Seneca Partners.
Vivos Therapeutics issues $2.09M unsecured note, net proceeds $1.5M, weekly $70K payments
Principal amount $2,093,340; net proceeds ~$1,500,000 after $587,340 OID and $6,000 fees.
Vivos Q3 revenue $6.8M (+78% seq, +76% YoY); operating loss widens to $4.7M
Revenue of $6.8M in Q3 2025, driven by first full quarter of Sleep Center of Nevada (SCN) acquisition; SCN added $2.2M diagnostic and $1.3M treatment revenue.
77% of participants had ≥50% reduction in OSA severity; 93% with severe OSA reached that threshold.
Vivos closes Sleep Center of Nevada acquisition for $6M cash + stock; issues $8.25M note
Acquired operating assets of SCN for $6M cash, 607k restricted shares ($1.5M at VWAP), plus contingent earn-out of up to $1.5M in stock.
Q2 2025 revenue $3.8M vs $4.1M YoY; gross margin fell to 55% from 65%.
Vivos closes $6M+stock acquisition of Sleep Center of Nevada; secures $11M+ financing
Acquired SCN for $6M cash + $1.5M in stock (607,287 shares) + assumption of liabilities; up to $1.5M earn-out in stock.
Vivos Therapeutics enters $1.1M convertible note to fund pending SCN acquisition
$1.1M principal convertible note to V-Co Investors 2 LLC; net funding $1M after $100k fee.
Vivos Q1 2025 product rev +8% YoY, net loss $3.9M; acquires Sleep Center of Nevada for up to $9M
Revenue $3.0M (-12% YoY) as pivot away from VIP service revenue; product revenue up 8% to $1.8M from appliance arch sales.
Vivos Therapeutics signs $9M deal to acquire Nevada sleep center operator SCN
Total consideration up to $9M: $6M cash + $1.5M stock at closing + $1.5M stock earn-out.
Vivos Therapeutics reports FY2024 revenue up 9% to $15M; operating loss narrows 35%
Revenue $15.0M (+9% YoY); product revenue increased 26%; gross profit $9.0M at 60% margin.
Vivos Therapeutics enters $3.3M ATM equity offering with H.C. Wainwright
Filed ATM offering agreement to sell up to $3,328,881 of common stock through H.C. Wainwright.
Vivos Therapeutics announces $3.5M registered direct offering of 709,220 shares and warrants
Gross proceeds of ~$3.5M from 709,220 shares at $4.935 each; warrants exercisable at $4.81 for two years.
Q3 2024 revenue $3.9M (+17% YoY); gross margin improved to 60% from 53%.
Vivos Therapeutics receives first FDA 510(k) clearance for oral device to treat pediatric OSA
FDA cleared Vivos' DNA appliance to treat moderate to severe OSA and snoring in children aged 6–17.
Vivos Therapeutics Q2 revenue up 19% YoY to $4.1M; operating expenses down 31%
Revenue $4.1M vs $3.4M YoY; gross margin improved to 65% from 62%.
Nasdaq panel grants Vivos continued listing subject to filing Q2 Form 10-Q by Aug 15, 2024
Panel granted continued listing on Nasdaq conditional on filing Form 10-Q for quarter ended June 30, 2024 by August 15, 2024.
Vivos Therapeutics updates Nasdaq compliance status after $7.5M private placement; hearing June 27
Received Nasdaq deficiency notice on May 16, 2024 for failing to meet $2.5M equity requirement.
Gross proceeds of $7.5M from sale of 3,220,266 shares/pre-funded warrants and 5-year warrants at $2.329/share to Seneca affiliate V-CO.
Vivos Therapeutics receives Nasdaq delisting notice for failing minimum equity requirement again
On May 16, 2024, Nasdaq notified Vivos that stockholders' equity fell below $2.5M as of March 31, 2024.
Q1 revenue $3.4M vs $3.8M YoY; gross margin 57% vs 61%.
Company believes it met $2.5M minimum equity requirement by March 19, 2024, via capital raises in Nov 2023 and Feb 2024.
Revenue for Q4 2023 was $3.2M and full year $13.8M, down from $4.0M and $16.0M in 2022, due to lower appliance revenue and VIP enrollments.
Nasdaq grants Vivos extension to March 19, 2024 for equity compliance; delisting risk persists
Regained minimum bid price compliance on Nov 9, 2023 after 1-for-25 reverse stock split.
Vivos raises $4.0M via private placement of stock and warrants; amends prior warrant
Sold 980,393 shares (or pre-funded warrants) at $4.08/share plus 980,393 Series A and 980,393 Series B warrants at $3.83.
Vivos Therapeutics implements 1-for-25 reverse stock split to meet Nasdaq minimum bid price
Reverse stock split at 1:25 ratio effective October 25, 2023; shares reduced from ~29.9M to ~1.2M.
Vivos Therapeutics receives Nasdaq delisting notice; plans to appeal
Nasdaq determined company failed to meet $1.00 minimum bid price as of Sept 20, 2023; delisting proceedings begun.
Effective July 31, 2026, the Board appointed Roman Franklin, age 42, as the Company’s Chief Financial Officer, and designated Mr. Franklin as the Company’s principal financial officer for purposes of the Securities Exchange Act of 1934, as amended.
On July 31, 2026, Bradford Amman resigned as Chief Financial Officer and Secretary of the Company, and from all other officer and committee positions held by reason of his employment, effective as of that date.
provided Dr. G. Dave Singh, the Company’s Chief Medical Officer (“Dr. Singh”), with notice of termination of his employment with the Company “for cause” pursuant to the terms Dr. Singh’s employment agreement with the Company, dated October 9, 2020.
he has resigned as a member of the Company’s board of directors (the “Board”), effective September 22, 2021.
Max materiality 0.85 · Median 0.65 · Most common event other_material